1. Home
  2. ELUT vs NRXP Comparison

ELUT vs NRXP Comparison

Compare ELUT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elutia Inc.

ELUT

Elutia Inc.

HOLD

Current Price

$1.09

Market Cap

46.5M

Sector

Health Care

ML Signal

HOLD

Logo NRX Pharmaceuticals Inc.

NRXP

NRX Pharmaceuticals Inc.

HOLD

Current Price

$1.88

Market Cap

54.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELUT
NRXP
Founded
2015
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.5M
54.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ELUT
NRXP
Price
$1.09
$1.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$6.00
$31.50
AVG Volume (30 Days)
189.1K
497.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
10.14
N/A
EPS
N/A
N/A
Revenue
$24,375,000.00
N/A
Revenue This Year
$26.95
N/A
Revenue Next Year
$24.84
$847.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$1.58
52 Week High
$3.46
$3.84

Technical Indicators

Market Signals
Indicator
ELUT
NRXP
Relative Strength Index (RSI) 50.86 49.93
Support Level $0.86 $1.65
Resistance Level $1.39 $1.99
Average True Range (ATR) 0.15 0.09
MACD -0.02 0.02
Stochastic Oscillator 25.00 63.49

Price Performance

Historical Comparison
ELUT
NRXP

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Share on Social Networks: